The FDA said in online documents that GlaxoSmithKline's vaccine Cervarix was effective against the two most dangerous strains of human papillomavirus based on a study involving more than 18,000 women. An FDA panel is set this week to evaluate the use of Cervarix in girls and women ages 10 to 25.

Full Story:

Related Summaries